Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.90
Change (%) Stock is Up 0.10 (0.93%)
Volume40,062
Data as of 03/28/17 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
03/23/17Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
01/30/17Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
01/04/17Eiger Completes $25 Million Debt Financing with Oxford Finance
01/03/17Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
Upcoming EventsMore >>
DateTitle
04/19/17
through
04/23/17
Eiger BioPharmaceuticals at EASL
LocationAmsterdamDK
06/06/17
through
06/09/17
Eiger BioPharmaceuticals at the Jefferies 2017 Global Healthcare Conference
09/10/17
through
09/12/17
Eiger BioPharmaceuticals at the Rodman & Renshaw 19th Annual Global Investment Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.